NCT01726972

Brief Summary

The proposed study aims to objectively assess 2-year clinical and radiographic results for the rate of glenoid component loosening in total shoulder arthroplasty (TSA). This retrospective radiographic review will provide evidence for equivalence or superiority in curtailing loosening, a known complication in arthroplasty, when a hemostatic agent is utilized in conjunction with cement at the glenoid.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2012

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2012

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

November 8, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 15, 2012

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

October 23, 2020

Status Verified

November 1, 2012

Enrollment Period

2.4 years

First QC Date

November 8, 2012

Last Update Submit

October 22, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Radiographic Loosening

    Radiographic loosening is defined by the presence of radiolucent lines at the bone-cement interface at 2 years. Lines are measured as being either not-present, less than 2mm or greater than/equal to 2mm, in addition to implant seating and the radiodensity between the flanges of the central peg.

    2 years

Eligibility Criteria

Age21 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who have previously undergone anatomic total shoulder arthroplasty for the treatment of glenohumeral osteoarthritis.

You may qualify if:

  • Patients must have completed at least 2 years follow-up following their total shoulder replacement
  • Patients must have had radiographic imaging obtained at that 2 years

You may not qualify if:

  • Patients less than 21 years of age
  • Patients who have been imprisoned since the time of surgery
  • Patients who are mentally impaired

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Denver, Colorado, 80218, United States

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 8, 2012

First Posted

November 15, 2012

Study Start

November 1, 2012

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

October 23, 2020

Record last verified: 2012-11

Locations